GLOBAL LIQUID BIOPSY MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Reports
  • GLOBAL LIQUID BIOPSY MARKET FORECAST 2020-2028

GLOBAL LIQUID BIOPSY MARKET FORECAST 2020-2028

The global liquid biopsy market is predicted to register a CAGR of 20.50% during the forecast years, and is estimated to generate a $5.76 billion revenue by 2028. The base year considered for the market study is 2019, and the forecast period is between 2020 and 2028. Liquid biopsy is swiftly gaining traction as an alternative or supplement for the tissue biopsy for applications in cancer, reproductive health, and transplant medicine. It analyzes and captures biomarkers, primarily cell-free DNA, found in body fluids like blood.

GLOBAL LIQUID BIOPSY MARKET FORECAST 2020-2028

Global Liquid Biopsy Market by Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma Cancer, Other Types of Cancer, Non-oncology Application) by Clinical Application (Treatment Monitoring, Prognosis and Reoccurrence Monitoring, Treatment Selection, Diagnosis and Screening) by Biomarker Type (Nucleic Acid, Protein, Extracellular Vesicles, Cells) by Analysis Platform (Ngs, Microarray, Pcr, Proteomics, Other Analysis Platforms) by Analysis Purpose (Early Detection/screening, Therapy Guidance, Monitoring, Diagnosis) by product (Circulating Tumor Dna (Ctdna), Circulating Tumor Cells (Ctcs), Cell-free Dna (Cfdna), Extracellular Vesicles and Others) by End-user (Physicians’ Office Laboratories, Hospitals, Clinical Diagnostic Laboratories) and by Geography.

Request free sample

The global liquid biopsy market is predicted to register a CAGR of 20.50% during the forecast years, and is estimated to generate a $5.76 billion revenue by 2028. The base year considered for the market study is 2019, and the forecast period is between 2020 and 2028. Liquid biopsy is swiftly gaining traction as an alternative or supplement for the tissue biopsy for applications in cancer, reproductive health, and transplant medicine. It analyzes and captures biomarkers, primarily cell-free DNA, found in body fluids like blood.

Key factors responsible for the global liquid biopsy market growth:

  • An upsurge in government initiatives
  • Increasing pervasiveness of cancer cases in the older population
  • Rising number of diagnostic centers
  • Growth of precision medicine
  • Emergence of tissue/tumor-agnostic drugs
  • Growing potential for liquid biopsy
  • Technological advancements

Global Liquid Biopsy MarketTo know more about this report, request a free sample copy

Prominent factors driving the global liquid biopsy market growth include, the rising pervasiveness of cancer among the aging population and the emergence of tissue or tumor-agnostic drugs. Aging causes the deterioration of the body’s immune system, making the geriatric population more susceptible to chronic diseases like cancer and cardiovascular conditions. Moreover, the emergence of tissue or tumor-agnostic drugs, targeting specific genetic variants within cancer, is an additional trend related to precision medicine.

In 2019, around 28.55% of the revenue share was secured by the lung cancer segment, under the therapeutic application category. Conversely, prostate cancer is anticipated to be the fastest-growing segment under the therapeutic application category. Regarding lung cancer, identifying the molecular profile of the tumor plays a vital role in deciding the further steps of the treatments. A conventional tissue biopsy is not an advisable method as recurrent biopsies are invasive and involve blood and tissue loss. Additionally, prostate cancer is the most common cancer among men, and treatment monitoring through tissue biopsy is highly impractical. Like colorectal cancer, the different screening and imaging methods remain inconsistent in their results.

The high cost of the testing and the lack of skilled professionals are the major factors hindering the liquid biopsy market growth. Moreover, the lack of strong reimbursement policies and standard guidelines for liquid biopsy tests also hamper market growth. Lab technicians also play a crucial role, as they are responsible for conducting standardized tests and receiving accurate results.

The report scope of the global liquid biopsy market covers segmentation analysis of therapeutic application, clinical application, biomarker type, analysis platform, analysis purpose, product, and end-user.

Market by Therapeutic Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma Cancer
  • Prostate Cancer
  • Non-oncology Applications
  • Others

Market by Clinical Application:

  • Treatment Monitoring
  • Treatment Selection
  • Diagnosis and Screening
  • Prognosis and Reoccurrence Monitoring

Market by Biomarker Type:

  • Extracellular vesicles
  • Nucleic acid
  • Cells
  • Protein

Market by Analysis Platform:

  • NGS
  • Proteomics
  • PCR
  • Microarray
  • Others

Market by Analysis Purpose:

  • Early detection/screening
  • Monitoring
  • Therapy Guidance
  • Diagnosis

Market by Product:

  • Cell-Free DNA (cfDNA)
  • Circulating Tumor DNA (cTDNA)
  • Extracellular vesicles
  • Circulating Tumor Cells (CTCs)
  • Others

Markey by End-user:

  • Hospitals
  • Physicians’ office laboratories
  • Clinical diagnostic laboratories

Geographically, the global liquid biopsy market has been segmented on the basis of four major regions, which includes:

  • North America: The United States & Canada
  • Europe: The United Kingdom, France, Germany, Italy, Belgium, Russia, Poland, and Rest of Europe
  • Asia Pacific: South Korea, China, Japan, India, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

Geographically, North America dominated the global liquid biopsy market in 2019, with a revenue share of 50.71%, and the region is anticipated to harbor the largest share by the end of the forecast period. The demand for liquid biopsy in the North America region is expected to increase in the upcoming years, owing to the increasing number of cancer cases. Moreover, the mortality rates may significantly reduce in the United States and Canada due to the presence of superior biopsy technologies, specializing in detecting diseases at early stages.

Conversely, the Asia Pacific is anticipated to be the fastest-growing region for liquid biopsy market. The region is projected to register the highest growth rate during the forecast period, as a result of lucrative opportunities in the market. Moreover, the countries in this region are highly populated, with China being the most abundant, followed by India.

The key market players of the global liquid biopsy market are: 

  • Becton Dickinson and Company (Bd)
  • Bio-Rad Laboratories Inc
  • Planmeca OY
  • Agilent Technologies Inc
  • Argon Medical Devices Inc
  • Others

Key strategies adopted by some of the global liquid biopsy companies:

In June 2020, Boston Scientific declared that the Centers for Medicare & Medicaid Services had accepted the application for a TPT payment category, to define single-use endoscopes. In April 2020, Bio-Rad Laboratories Inc announced the acquisition of Celsee Inc. However, the standings of the asset were concealed.

Key trends of the global liquid biopsy market:

  • New players are approaching venture capitalists for entering niche markets like liquid biopsy.
  • The growing number of cancer patients has augmented market growth.
  • Emerging economies are experiencing expansions.
  • Clinical diagnostic laboratories are the fastest-growing end-user.
  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • RISING GOVERNMENT INITIATIVES
      • GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
      • GROWING NUMBER OF DIAGNOSTIC CENTERS
      • GROWTH OF PRECISION MEDICINE
      • EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
      • RISING POTENTIAL OF THE LIQUID BIOPSY
      • TECHNOLOGICAL ADVANCEMENT
    •    KEY RESTRAINTS
      • LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
      • POOR COMPENSATION STRUCTURES
      • HIGH COST OF THE TEST
      • LACK OF REIMBURSEMENT
      • LACK OF SKILLED PROFESSIONALS
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • KEY LIQUID BIOPSY INITIATIVES
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  3. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  4. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACID
    • PROTEIN
    • EXTRACELLULAR VESICLES
    • CELLS
  5. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORMS
  6. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  7. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  8. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  9. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA & NEW ZEALAND
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • BECTON DICKINSON AND COMPANY (BD)
    • F HOFFMANN-LA ROCHE
    • BIO-RAD LABORATORIES INC
    • B BRAUN MELSUNGEN AG
    • BOSTON SCIENTIFIC CORPORATION
    • QIAGEN NV
    • PLANMECA OY
    • COOK MEDICAL INC
    • AD-TECH MEDICAL INSTRUMENT CORP
    • AGILENT TECHNOLOGIES INC
    • ARGON MEDICAL DEVICES INC
    • CINTEC MEDICAL LTD
    • FISCHER MEDICAL TECHNOLOGIES LLC
    • IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL

TABLE LIST

TABLE 1: MARKET SNAPSHOT – LIQUID BIOPSY

TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES

TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES

TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS

TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 23: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 25: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 26: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 27: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 28: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURE LIST

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2019

FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2020-2028 (IN $ MILLION)

FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2020-2028 (IN $ MILLION)

FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2020-2028 (IN $ MILLION)

FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2020-2028 (IN $ MILLION)

FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2020-2028 (IN $ MILLION)

FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2020-2028 (IN $ MILLION)

FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2020-2028 (IN $ MILLION)

FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2019

FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2020-2028 (IN $ MILLION)

FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2020-2028 (IN $ MILLION)

FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2020-2028 (IN $ MILLION)

FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2020-2028 (IN $ MILLION)

FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2019

FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2020-2028 (IN $ MILLION)

FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2020-2028 (IN $ MILLION)

FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2020-2028 (IN $ MILLION)

FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2020-2028 (IN $ MILLION)

FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2019

FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2020-2028 (IN $ MILLION)

FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2020-2028 (IN $ MILLION)

FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2020-2028 (IN $ MILLION)

FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2020-2028 (IN $ MILLION)

FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2020-2028 (IN $ MILLION)

FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2019

FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2020-2028 (IN $ MILLION)

FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2020-2028 (IN $ MILLION)

FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2020-2028 (IN $ MILLION)

FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2020-2028 (IN $ MILLION)

FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2019

FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2020-2028 (IN $ MILLION)

FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2020-2028 (IN $ MILLION)

FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2020-2028 (IN $ MILLION)

FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2020-2028 (IN $ MILLION)

FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2019

FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS’ OFFICE LABORATORIES, 2020-2028 (IN $ MILLION)

FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2020-2028 (IN $ MILLION)

FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2020-2028 (IN $ MILLION)

FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 44: THE UNITED STATES LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 47: THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 55: ASIA PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 64: REST OF ASIA PACIFIC LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)

  1. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  2. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  3. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACID
    • PROTEIN
    • EXTRACELLULAR VESICLES
    • CELLS
  4. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORMS
  5. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  6. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  7. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  8. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA & NEW ZEALAND
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now